SIM
ATXI

Spark Investment Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Spark Investment Management’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-13
Closed -$87K – 586
2019
Q3 		$87K Sell
13
-8
-38% -$54.5K 0.01% 366
2019
Q2 		$148K Sell
21
-6
-22% -$34.7K 0.01% 485
2019
Q1 		$144K Buy
+27
New +$172K 0.01% 539
2017
Q4 		– Sell
-11
Closed -$69K – 830
2017
Q3 		$69K Buy
+11
New +$80.8K ﹤0.01% 683

Other funds holding ATXI

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Spark Investment Management's ATXI Position: Q4 2019 in Review

Spark Investment Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2019, closing a stake of 13 shares — an estimated $87K sold.

Spark Investment Management first reported a position in ATXI in Q3 2017 and held it in 4 quarters. The position peaked at $148K in Q2 2019. 13 funds tracked by Wall St. Rank hold ATXI as of Q4 2019.

  • Spark Investment Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Spark Investment Management sold 13 Avenue Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $87K.
  • Spark Investment Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q3 2017 and held it in 4 quarters.
  • Spark Investment Management's Avenue Therapeutics, Inc. Common Stock position peaked at $148K in Q2 2019.
  • 13 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Spark Investment Management's 13F filing for Q4 2019, filed 11 Feb 2020.